Aurobindo Pharma Subsidiary Launches ADQUEY in US, Targets $1.3B Dermatology Market
Aurobindo Pharma Ltd 路 Press Release 路 01 Oct 2026, 2:58 am
Aurobindo Pharma Subsidiary Launches ADQUEY in US, Targets $1.3B Dermatology Market Aurobindo Pharma鈥檚 step-down subsidiary, Acrotech Biopharma, launched ADQUEY (difamilast 1% ointment) in the U.S. on 30th Sep'26, marking its strategic entry into dermatology. Discovered by Otsuka Pharmaceutical and licensed to Acrotech, the non-steroidal topical PDE4 inhibitor treats mild-to-moderate atopic dermatitis in patients aged two and older. The product addresses an addressable U.S. market estimated at US$ 1.3 billion for the MAT ending Jul'26 (IQVIA). To support commercialization, Acrotech established a dedicated dermatology business unit covering marketing, sales, and field engagement.
Original exchange filing (PDF)
More announcements from Aurobindo Pharma Ltd
- Intimation of classification of US FDA inspection at Lannet Company LLC, a wholly owned subsidiary of Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company. 路 12 Nov 2026
- Submission of Earning Call Transcript for Q2FY27. 路 11 Nov 2026
- Unit-2 of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company received Establishment Inspection Report from US FDA with classification as "Voluntary Action Indicated". 路 11 Nov 2026
- Intimation of investors / analysts meet to be held on 17.11.2026. 路 09 Nov 2026
- Intimation of investor / analysts meet to be held on 16.09.2026. 路 09 Nov 2026
- Submission of Financial results for the Quarter and Half year ended September 30, 2026. 路 05 Nov 2026
- Reappointment of Mr. M. R. Kumar as Independent Director of the Company for second term with effect from April 1, 2027. 路 05 Nov 2026
- Transfer of ownership of Auro Pharma LLC, Russia from Auroactive Pharma Private Limited to Auropharm Overseas Limited, Wholly Owned subsidiaries of the Company. 路 05 Nov 2026
